

RECEIVED  
CENTRAL FAX CENTER  
JUN 30 2005

**FAX**

GlaxoSmithKline

To Attn: Examiner David J. STEADMAN, Group 1652

Company USPTO

Fax (703) 872-9306

From Johnie Jones

Tel (919) 483-7867; Facsimile: (919) 483-5730

E-mail [Johnie.X.Jones@gsk.com](mailto:Johnie.X.Jones@gsk.com)

Date June 30, 2005

Pages Including cover 8

Subject Application of: Randy K. Bledsoe, et al.  
U.S. Serial No.: 10/600,751  
Filed: 06/20/2003  
Title: *Structure Of A Glucocorticoid Receptor Ligand  
Binding Domain Comprising An Expanded  
Binding Pocket And Methods Employing Same*  
Attorney Docket No. PU4803US

GlaxoSmithKline  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709

Tel: 919 483 2100  
[www.gsk.com](http://www.gsk.com)

**Attached:**

1. Transmittal Form
2. Response to Restriction Requirement
3. Preliminary Amendment

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Doc

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/600,751
	Filing Date	6/20/2003
	First Named Inventor	Randy K. BLEDSOE
	Art Unit	1652
	Examiner Name	David J. Steadman
Total Number of Pages In This Submission	Attorney Docket Number	PU4803US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks Applicants believe that no fee is required for this submission. However, the Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	GlaxoSmithKline	
Signature	<i>Kathryn L. Coulter</i>	
Printed name	Kathryn L. Coulter	
Date	June 30, 2005	Reg. No. 45,889

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature	<i>Johnnie Jones</i>		
Typed or printed name	Johnnie Jones	Date	June 30, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Atty. Docket No.:PU4631US

**RECEIVED**  
**CENTRAL FAX CENTER**  
**JUN 30 2005**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Bledsoe *et al.*

Application No.: 10/600,751

Confirmation No. 5089

Filed: June 20, 2003

Art Unit: 1652

Examiner: David J. Steadman

For: STRUCTURE OF A GLUCOCORTICOID RECEPTOR LIGAND  
BINDING DOMAIN COMPRISING AN EXPANDED BINDING POCKET AND  
METHODS EMPLOYING SAME

Customer No.: 23347

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**PRELIMINARY AMENDMENT**

Sir:

Please amend the above-referenced application as follows:

**Amendments to the Specification begin on page 2 of this paper.**

**Remarks begin on page 3 of this paper.**